Emilie Barbier

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

Anthony Dohan, B. Gallix, Boris Guiu et al. · Gut · 2019 · 138 citations

Medicine, Oncology, Radiology +17

Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers

Mehdi Karoui, Anne Rullier, Guillaume Piessen et al. · Annals of Surgery · 2019 · 137 citations

Medicine, Oncology, Surgery +17

Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study

Jean–Marc Phelip, Jérôme Desrame, Julien Edeline et al. · Journal of Clinical Oncology · 2021 · 134 citations

Medicine, Oncology, Pharmacotherapy +12

Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma

Jean–Louis Jouve, Thierry Lecomte, Olivier Bouché et al. · Journal of Hepatology · 2019 · 114 citations

Medicine, Oncology, Pharmacology +13

Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study

Jean-Marc Phelip, Julien Edeline, Jean‐Frédéric Blanc et al. · Digestive and Liver Disease · 2018 · 53 citations

Medicine, Oncology, Pharmacology +8